This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, recent events and analyst opinion, patent information, a 10-year disease incidence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Datamonitor Healthcare estimates that in 2016, there were 70,700 incident cases of Hodgkin’s lymphoma worldwide, and expects that number to increase to 77,400 incident cases by 2025.
•  Incidence rates are slightly higher in males compared to females. The approved drugs in the Hodgkin’s lymphoma space target antibody-drug conjugate, cluster of differentiation 30/tumor necrosis factor receptor superfamily member 8, microtubules, deoxyribonucleic acid, the immune system, and programmed death-1 receptor/programmed death ligands. The majority of approved drugs are administered via the intravenous route.
• The majority of industry-sponsored drugs in active clinical development for Hodgkin’s lymphoma are in Phase II, with no drugs in Phase III.
• Therapies in the pipeline for Hodgkin’s lymphoma focus on a wide variety of targets. The majority of the pipeline drugs in development are administered via the oral and intravenous routes, with only one product being tested in an intratumoral formulation.
• High-impact upcoming events for drugs in the Hodgkin’s lymphoma space comprise topline Phase IIa trial results for AFM13, and a supplemental CHMP opinion for Adcetris.
• The overall likelihood of approval of a Phase I hematologic asset is 10.9%, and the average probability a drug advances from Phase III is 57.6%. Drugs, on average, take 8.7 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
• There have been 41 licensing and asset acquisition deals involving Hodgkin’s lymphoma drugs during 2013–18. The largest deal was the $1,410m exclusive licensing agreement in August 2017 between Dermira and Roche/Genentech for the development and commercialization of lebrikizumab.
• The clinical trials distribution across Phase I–IV indicates that the vast majority of trials for Hodgkin’s lymphoma have been in the early and mid-phases of development, with 94% of trials in Phase I–II, and only 6% in Phase III–IV.
• The US has a substantial lead in the number of Hodgkin’s lymphoma clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.
• Clinical trial activity in the Hodgkin’s lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin’s lymphoma, with 46 trials.
• Takeda leads industry sponsors with by far the highest number of clinical trials for Hodgkin’s lymphoma, followed by Merck & Co.